{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T15:49:38Z","timestamp":1792165778749,"version":"4.4.0"},"reference-count":36,"publisher":"American Association for Cancer Research (AACR)","issue":"8","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2006,4,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The immunoglobulin receptor of B-cell lymphomas constitutes a specific tumor antigen (idiotype) and a target for active immunotherapy. Encouraging results have been reported in phase II trials after s.c. vaccination of follicular lymphoma patients during clinical remission with idiotype produced from eukaryotic cell lines and coupled to an immunogenic carrier macromolecule. We have developed a good manufacturing protocol for rapid expression of idiotype vaccines as recombinant Fab fragments in Escherichia coli. The objectives of this trial were to show safety and feasibility of intradermal immunization with this vaccine and to investigate whether immune responses were induced by this immunization route. Patients (n = 18) with advanced B-cell malignancies received repetitive intradermal vaccinations with 0.5 to 1.65 mg recombinant idiotype Fab fragment mixed with lipid-based adjuvant in combination with 150 \u03bcg granulocyte macrophage colony-stimulating factor s.c. at the same location. The patients' immune status was assessed by flow cytometry of peripheral blood lymphocytes and concomitant hepatitis B vaccination. Cellular and humoral immune responses to the vaccine were assessed by enzyme-linked immunospot and ELISA. Side effects of a total of 65 vaccinations were mild and did not affect the immunization schedule. No patient developed hepatitis B surface antibodies (anti-HBs) after two hepatitis B immunizations. Of 17 evaluable patients, five developed specific anti-vaccine antibodies, and eight developed anti-Fab T-cell responses. T-cell reactivity was independent of the cellular immune status and was idiotype specific as shown by statistical regression analysis (P = 0.0024) and epitope mapping studies. Intradermal administration of uncoupled recombinant idiotype with appropriate adjuvants may overcome profound clinical immunosuppression and induce specific immune responses. (Cancer Res 2006; 66(8): 4496-502)<\/jats:p>","DOI":"10.1158\/0008-5472.can-05-4233","type":"journal-article","created":{"date-parts":[[2006,4,17]],"date-time":"2006-04-17T16:20:21Z","timestamp":1145290821000},"page":"4496-4502","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Phase I Trial of a Novel Intradermal Idiotype Vaccine in Patients with Advanced B-Cell Lymphoma: Specific Immune Responses Despite Profound Immunosuppression"],"prefix":"10.1158","volume":"66","author":[{"given":"Cristina","family":"Bertinetti","sequence":"first","affiliation":[{"name":"1Department of Hematology\/Oncology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Zirlik","sequence":"additional","affiliation":[{"name":"1Department of Hematology\/Oncology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Heining-Mikesch","sequence":"additional","affiliation":[{"name":"1Department of Hematology\/Oncology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Ihorst","sequence":"additional","affiliation":[{"name":"2Center of Clinical Trials, Freiburg University Medical Center, Freiburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heide","family":"Dierbach","sequence":"additional","affiliation":[{"name":"1Department of Hematology\/Oncology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelius F.","family":"Waller","sequence":"additional","affiliation":[{"name":"1Department of Hematology\/Oncology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hendrik","family":"Veelken","sequence":"additional","affiliation":[{"name":"1Department of Hematology\/Oncology and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2006,4,17]]},"reference":[{"key":"2022061622143273300_B1","doi-asserted-by":"crossref","unstructured":"Campbell MJ, Esserman L, Levy R. Immunotherapy of established murine B cell lymphoma. Combination of idiotype immunization and cyclophosphamide. J Immunol\u20081988; 141: 3227\u201333.","DOI":"10.4049\/jimmunol.141.9.3227"},{"key":"2022061622143273300_B2","doi-asserted-by":"crossref","unstructured":"Kaminski MS, Kitamura K, Maloney DG, Levy R. Idiotype vaccination against murine B cell lymphoma. Inhibition of tumor immunity by free idiotype protein. J Immunol\u20081987; 138: 1289\u201396.","DOI":"10.4049\/jimmunol.138.4.1289"},{"key":"2022061622143273300_B3","doi-asserted-by":"crossref","unstructured":"George AJ, Tutt AL, Stevenson FK. Anti-idiotypic mechanisms involved in suppression of a mouse B cell lymphoma, BCL1. J Immunol\u20081987; 138: 628\u201334.","DOI":"10.4049\/jimmunol.138.2.628"},{"key":"2022061622143273300_B4","doi-asserted-by":"crossref","unstructured":"Sakato N, Eisen HN. Antibodies to idiotypes of isologous immunoglobulins. J Exp Med\u20081975; 141: 1411\u201326.","DOI":"10.1084\/jem.141.6.1411"},{"key":"2022061622143273300_B5","doi-asserted-by":"crossref","unstructured":"Campbell MJ, Esserman L, Byars NE, Allison AC, Levy R. Idiotype vaccination against murine B cell lymphoma. Humoral and cellular requirements for the full expression of antitumor immunity. J Immunol\u20081990; 145: 1029\u201336.","DOI":"10.4049\/jimmunol.145.3.1029"},{"key":"2022061622143273300_B6","doi-asserted-by":"crossref","unstructured":"Kwak LW, Young HA, Pennington RW, Weeks SD. Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte\/macrophage colony-stimulating factor primes mice for a protective T-cell response. Proc Natl Acad Sci U S A\u20081996; 93: 10972\u20137.","DOI":"10.1073\/pnas.93.20.10972"},{"key":"2022061622143273300_B7","doi-asserted-by":"crossref","unstructured":"Lauritzsen GF, Weiss S, Dembic Z, Bogen B. Naive idiotype-specific CD4+ T cells and immunosurveillance of B-cell tumors. Proc Natl Acad Sci U S A\u20081994; 91: 5700\u20134.","DOI":"10.1073\/pnas.91.12.5700"},{"key":"2022061622143273300_B8","doi-asserted-by":"crossref","unstructured":"Kwak LW, Campbell MJ, Czerwinski DK, Hart S, Miller RA, Levy R. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N Engl J Med\u20081992; 327: 1209\u201315.","DOI":"10.1056\/NEJM199210223271705"},{"key":"2022061622143273300_B9","doi-asserted-by":"crossref","unstructured":"Hsu FJ, Caspar CB, Czerwinski D, et al. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma-long-term results of a clinical trial. Blood\u20081997; 89: 3129\u201335.","DOI":"10.1182\/blood.V89.9.3129"},{"key":"2022061622143273300_B10","doi-asserted-by":"crossref","unstructured":"Bendandi M, Gocke CD, Kobrin CB, et al. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat Med\u20081999; 5: 1171\u20137.","DOI":"10.1038\/13928"},{"key":"2022061622143273300_B11","doi-asserted-by":"crossref","unstructured":"Nelson EL, Li X, Hsu FJ, et al. Tumor-specific, cytotoxic T-lymphocyte response after idiotype vaccination for B-cell, non-Hodgkin's lymphoma. Blood\u20081996; 88: 580\u20139.","DOI":"10.1182\/blood.V88.2.580.bloodjournal882580"},{"key":"2022061622143273300_B12","doi-asserted-by":"crossref","unstructured":"Weng WK, Czerwinski D, Timmerman J, Hsu FJ, Levy R. Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype. J Clin Oncol\u20082004; 22: 4717\u201324.","DOI":"10.1200\/JCO.2004.06.003"},{"key":"2022061622143273300_B13","doi-asserted-by":"crossref","unstructured":"Timmerman JM, Czerwinski DK, Davis TA, et al. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood\u20082002; 99: 1517\u201326.","DOI":"10.1182\/blood.V99.5.1517"},{"key":"2022061622143273300_B14","doi-asserted-by":"crossref","unstructured":"Hsu FJ, Benike C, Fagnoni F, et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med\u20081996; 2: 52\u20138.","DOI":"10.1038\/nm0196-52"},{"key":"2022061622143273300_B15","doi-asserted-by":"crossref","unstructured":"Osterborg A, Yi Q, Henriksson L, et al. Idiotype immunization combined with granulocyte-macrophage colony-stimulating factor in myeloma patients induced type I, major histocompatibility complex-restricted, CD8- and CD4-specific T-cell responses. Blood\u20081998; 91: 2459\u201366.","DOI":"10.1182\/blood.V91.7.2459.2459_2459_2466"},{"key":"2022061622143273300_B16","doi-asserted-by":"crossref","unstructured":"Massaia M, Borrione P, Battaglio S, et al. Idiotype vaccination in human myeloma: generation of tumor-specific immune responses after high-dose chemotherapy. Blood\u20081999; 94: 673\u201383.","DOI":"10.1182\/blood.V94.2.673.414k30_673_683"},{"key":"2022061622143273300_B17","doi-asserted-by":"crossref","unstructured":"Carroll WL, Thielemans K, Dilley J, Levy R. Mouse x human heterohybridomas as fusion partners with human B cell tumors. J Immunol Methods\u20081986; 89: 61\u201372.","DOI":"10.1016\/0022-1759(86)90032-3"},{"key":"2022061622143273300_B18","doi-asserted-by":"crossref","unstructured":"Hurvitz SA, Timmerman JM. Current status of therapeutic vaccines for non-Hodgkin's lymphoma. Curr Opin Oncol\u20082005; 17: 432\u201340.","DOI":"10.1097\/01.cco.0000174040.52427.83"},{"key":"2022061622143273300_B19","doi-asserted-by":"crossref","unstructured":"Skerra A. A general vector, pASK84, for cloning, bacterial production, and single-step purification of antibody Fab fragments. Gene\u20081994; 141: 79\u201384.","DOI":"10.1016\/0378-1119(94)90131-7"},{"key":"2022061622143273300_B20","doi-asserted-by":"crossref","unstructured":"Osterroth F, Alkan O, Mackensen A, et al. Rapid expression cloning of human immunoglobulin Fab fragments for the analysis of antigen specificity of B cell lymphomas and anti-idiotype lymphoma vaccination. J Immunol Methods\u20081999; 229: 141\u201353.","DOI":"10.1016\/S0022-1759(99)00111-8"},{"key":"2022061622143273300_B21","doi-asserted-by":"crossref","unstructured":"Osterroth F, Garbe A, Fisch P, Veelken H. Stimulation of cytotoxic T cells against idiotype immunoglobulin of malignant lymphoma with protein-pulsed or idiotype-transduced dendritic cells. Blood\u20082000; 95: 1342\u20139.","DOI":"10.1182\/blood.V95.4.1342.004k19_1342_1349"},{"key":"2022061622143273300_B22","doi-asserted-by":"crossref","unstructured":"Kenney RT, Frech SA, Muenz LR, Villar CP, Glenn GM. Dose sparing with intradermal injection of influenza vaccine. N Engl J Med\u20082004; 351: 2295\u2013301.","DOI":"10.1056\/NEJMoa043540"},{"key":"2022061622143273300_B23","doi-asserted-by":"crossref","unstructured":"Ott G, Barchfeld GL, Chernoff D, Radhakrishnan R, van Hoogevest P, Van Nest G. MF59. Design and evaluation of a safe and potent adjuvant for human vaccines. Pharm Biotechnol\u20081995; 6: 277\u201396.","DOI":"10.1007\/978-1-4615-1823-5_10"},{"key":"2022061622143273300_B24","doi-asserted-by":"crossref","unstructured":"Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol\u20081999; 17: 1244.","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"2022061622143273300_B25","doi-asserted-by":"crossref","unstructured":"WHO. Reporting the results of cancer treatment. Cancer\u20081981; 47: 207.","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6"},{"key":"2022061622143273300_B26","doi-asserted-by":"crossref","unstructured":"Liang KY, Zegel SL. Longitudinal data analysis using generalized linear models. Biometrika\u20081986; 73: 13\u201322.","DOI":"10.1093\/biomet\/73.1.13"},{"key":"2022061622143273300_B27","doi-asserted-by":"crossref","unstructured":"Totterman TH, Carlsson M, Simonsson B, Bengtsson M, Nilsson K. T-cell activation and subset patterns are altered in B-CLL and correlate with the stage of the disease. Blood\u20081989; 74: 786\u201392.","DOI":"10.1182\/blood.V74.2.786.786"},{"key":"2022061622143273300_B28","unstructured":"Kimby E, Mellstedt H, Nilsson B, Bjorkholm M, Holm G. Differences in blood T and NK cell populations between chronic lymphocytic leukemia of B cell type (B-CLL) and monoclonal B-lymphocytosis of undetermined significance (B-MLUS). Leukemia\u20081989; 3: 501\u20134."},{"key":"2022061622143273300_B29","doi-asserted-by":"crossref","unstructured":"Scrivener S, Goddard RV, Kaminski ER, Prentice AG. Abnormal T-cell function in B-cell chronic lymphocytic leukaemia. Leuk Lymphoma\u20082003; 44: 383\u20139.","DOI":"10.1080\/1042819021000029993"},{"key":"2022061622143273300_B30","doi-asserted-by":"crossref","unstructured":"Bacik I, Snyder HL, Anton LC, et al. Introduction of a glycosylation site into a secreted protein provides evidence for an alternative antigen processing pathway: transport of precursors of major histocompatibility complex class I-restricted peptides from the endoplasmic reticulum to the cytosol. J Exp Med\u20081997; 186: 479\u201387.","DOI":"10.1084\/jem.186.4.479"},{"key":"2022061622143273300_B31","doi-asserted-by":"crossref","unstructured":"Wood P, Elliott T. Glycan-regulated antigen processing of a protein in the endoplasmic reticulum can uncover cryptic cytotoxic T cell epitopes. J Exp Med\u20081998; 188: 773\u20138.","DOI":"10.1084\/jem.188.4.773"},{"key":"2022061622143273300_B32","doi-asserted-by":"crossref","unstructured":"Levitsky HI, Montgomery J, Ahmadzadeh M, et al. Immunization with granulocyte-macrophage colony-stimulating factor-transduced, but not B7\u20131-transduced, lymphoma cells primes idiotype-specific T cells and generates potent systemic antitumor immunity. J Immunol\u20081996; 156: 3858\u201365.","DOI":"10.4049\/jimmunol.156.10.3858"},{"key":"2022061622143273300_B33","doi-asserted-by":"crossref","unstructured":"Rosen HR, Stierer M, Wolf HM, Eibl MM. Impaired primary antibody responses after vaccination against hepatitis B in patients with breast cancer. Breast Cancer Res Treat\u20081992; 23: 233\u201340.","DOI":"10.1007\/BF01833520"},{"key":"2022061622143273300_B34","doi-asserted-by":"crossref","unstructured":"Neelapu SS, Kwak LW, Kobrin CB, et al. Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma. Nat Med\u20082005; 11: 986\u201391.","DOI":"10.1038\/nm1290"},{"key":"2022061622143273300_B35","doi-asserted-by":"crossref","unstructured":"Trojan A, Schultze JL, Witzens M, et al. Immunoglobulin framework-derived peptides function as cytotoxic T-cell epitopes commonly expressed in B-cell malignancies. Nat Med\u20082000; 6: 667\u201372.","DOI":"10.1038\/76243"},{"key":"2022061622143273300_B36","doi-asserted-by":"crossref","unstructured":"Baskar S, Kobrin CB, Kwak LW. Autologous lymphoma vaccines induce human T cell responses against multiple, unique epitopes. J Clin Invest\u20082004; 113: 1498\u2013510.","DOI":"10.1172\/JCI20312"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/66\/8\/4496\/2561251\/4496.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/66\/8\/4496\/2561251\/4496.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,7]],"date-time":"2023-05-07T02:33:13Z","timestamp":1683426793000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/66\/8\/4496\/527467\/Phase-I-Trial-of-a-Novel-Intradermal-Idiotype"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,4,15]]},"references-count":36,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2006,4,17]]},"published-print":{"date-parts":[[2006,4,15]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-05-4233","relation":{},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,4,15]]}}}